Company Overview - WEBUY GLOBAL LTD is a technology-driven company focused on transforming community e-commerce and travel across Southeast Asia, utilizing predictive AI and personalized recommendations to enhance its group-buy model [5]. Offering Details - The company announced the closing of its offering of 721,918 Class A ordinary shares and pre-funded warrants to purchase up to 100,000 Class A ordinary shares, generating gross proceeds of approximately $3 million before deducting fees and expenses [1][2]. - D. Boral Capital LLC served as the exclusive placement agent for this offering, with legal counsel provided by Ortoli Rosenstatdt LLP for the company and Hunter Taubman Fischer & Li LLC for the placement agent [2]. Regulatory Compliance - The securities were offered under an effective registration statement on Form F-1, which was filed with the U.S. Securities and Exchange Commission (SEC) and declared effective on June 27, 2025. Multiple post-effective amendments were filed in July 2025, with the final amendment declared effective on July 18, 2025 [3].

Core Insights - iRhythm Technologies has formed a strategic partnership with Lucem Health to enhance early detection of undiagnosed arrhythmias in high-risk patient populations [1][2][3] - The collaboration aims to shift from reactive to proactive healthcare, utilizing AI to identify arrhythmia risks before symptoms manifest [2][3] - The partnership targets over 27 million individuals in the U.S. who could benefit from proactive cardiac monitoring [2][8] Company Overview - iRhythm Technologies is a digital health leader focused on solutions that detect, predict, and prevent disease, utilizing wearable biosensors and cloud-based analytics [18] - Lucem Health specializes in AI-driven early disease detection, aiming to improve clinical outcomes and resource allocation in healthcare [19] Partnership Details - The collaboration will leverage Lucem Health's AI platform and iRhythm's diagnostic services to enable earlier identification of arrhythmia risks [2][3] - The first commercial offering will focus on patients with conditions like Type 2 diabetes, chronic kidney disease, chronic obstructive pulmonary disease, and coronary artery disease [4][6] Clinical Impact - Early pilot testing indicates improved targeting of patient populations at risk for arrhythmias, facilitating earlier clinical engagement [7] - The predictive AI solution is expected to enhance arrhythmia detection among an estimated 27 million undiagnosed patients in the U.S., potentially reducing healthcare resource utilization and costs [8][15] Economic Considerations - Cardiac arrhythmias affect approximately 1 in 20 U.S. adults, and untreated cases can lead to severe health complications, emphasizing the need for early detection [9][11] - Research shows that patients with arrhythmias incur significantly higher healthcare costs, reinforcing the economic case for earlier detection and intervention [13][14]

Group 1 - Webuy Global Ltd. has been included in the Financial Times and Statista's "High-Growth Companies Asia-Pacific 2025" list, recognizing its outstanding performance based on compound annual revenue growth from 2020 to 2023 [1][2] - The 2025 list highlights companies that have demonstrated exceptional resilience and innovation during global uncertainty, with Singapore leading in total entries [2] - The top sectors represented in the ranking include IT and software, financial services, and consumer platforms [2] Group 2 - Bin Xue, CEO and Co-Founder of Webuy, expressed pride in the recognition, attributing it to the company's commitment to innovation, operational excellence, and customer-centric growth [2] - Webuy Global Ltd. focuses on transforming community e-commerce and travel in Southeast Asia through a group-buy model enhanced by predictive AI and personalized recommendations [3] - The company's travel vertical offers curated itineraries and real-time support via its proprietary AI Travel Consultant, aiming to improve the lives of millions in the region [3]